Oneness Biotech Co

Oneness Biotech Co FCF Margin

The Free Cash Flow Margin of Oneness Biotech Co (4743.TWO) as of Oct 30, 2026 is -376.96 %. In the previous year, Free Cash Flow Margin was -338.22 % — a change of 11.45% (lower).

FCF Margin

-376.96 %

YoY

11.45%

Last updated:

Free Cash Flow Margin of Oneness Biotech Co is 2025 -376.96 % . Free Cash Flow Margin of Oneness Biotech Co was 2024 -338.22 % . It decreases by 11.45% lower compared to the previous year.

The Oneness Biotech Co FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2018
-914.13 TWD
Jan 1, 2019
-1,933.41 TWD
Jan 1, 2020
11.70 TWD
Jan 1, 2021
-591.79 TWD
Jan 1, 2022
-91.05 TWD
Jan 1, 2023
-560.08 TWD
Jan 1, 2024
-338.22 TWD
Jan 1, 2025
-376.96 TWD
The Oneness Biotech Co FCF Margin history
YEARFCF MarginYoY
-376.96 %+11.45%
-338.22 %-39.61%
-560.08 %+515.13%
-91.05 %-84.61%
-591.79 %-5,159.85%
11.70 %-100.60%
-1,933.41 %+111.50%
-914.13 %-95.06%
-18,494.01 %+304.76%
-4,569.17 %+75.46%
-2,604.12 %-8.31%
-2,840.17 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Oneness Biotech Co Stock analysis

What does Oneness Biotech Co do? Oneness Biotech Co., Ltd. generates revenue through the research and development of new drugs and the sale of pharmaceutical products and health products. The company focuses on health supplies, health food, and healthy food as its main products, which are distributed domestically. It also develops new drugs for treating chronic diabetic foot ulcers and anticancer drugs, targeting the domestic market for both its existing and new product lines. The firm's primary customers are domestic consumers seeking health and pharmaceutical solutions, including those requiring wound healing treatments for diabetic foot ulcers and anticancer therapies. Its product portfolio includes health supplies, health food, healthy food, and specialized drug developments, all sold within Taiwan's domestic market. Oneness Biotech's business model centers on developing and selling health and pharmaceutical products, with a particular emphasis on niche medical applications like diabetic foot ulcer treatments and cancer drugs. The company leverages its domestic distribution network to reach consumers interested in health-focused solutions and specialized medical treatments. Oneness Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Oneness Biotech Co stock

Free Cash Flow Margin of Oneness Biotech Co is -376.96 % in 2025.

Free Cash Flow Margin of Oneness Biotech Co changed from -338.22 % to -376.96 %, representing a 11.45% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin Oneness Biotech Co since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's Oneness Biotech Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Oneness Biotech Co

All Key Metrics — Oneness Biotech Co